| DESCRIPTION | - AGATA et al., Int Immunol, (19960000), vol. 8, pages 765 - 72 | - |
| DESCRIPTION | - ASCIERTO et al., J Clin Oncol., (20170000), vol. 35 | - |
| DESCRIPTION | - BENNETT et al., J Immunol, (20030000), vol. 170, pages 711 - 8 | - |
| DESCRIPTION | - BETTINI M. et al., J. Immunol., (20110000), vol. 187, pages 3493 - 3498 | - |
| DESCRIPTION | - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426 | - |
| DESCRIPTION | - BLACKBURN S D et al., Nat. Immunol., (20090000), vol. 10, pages 29 - 37 | - |
| DESCRIPTION | - BLANK et al., Cancer Immunol. Immunother., (20050000), vol. 54, pages 307 - 314 | - |
| DESCRIPTION | - BROWN et al., J. Immunol., (20030000), vol. 170, pages 1257 - 66 | - |
| DESCRIPTION | - CAMISASCHI C et al., J. Immunol., (20100000), vol. 184, pages 6545 - 6551 | - |
| DESCRIPTION | - CARTER et al., Eur J Immunol, (20020000), vol. 32, pages 634 - 43 | - |
| DESCRIPTION | - CONDEELIS; WEISSLEDER, Cold Spring Harb. Perspect. Biol., (20100000), vol. 2, no. 12, page a003848 | - |
| DESCRIPTION | - DONG et al., J. Mol. Med., (20030000), vol. 81, pages 281 - 7 | - |
| DESCRIPTION | - DONG et al., Nat. Med., (20020000), vol. 8, pages 787 - 9 | - |
| DESCRIPTION | - DONG H et al., Nat Med., (19990000), vol. 5, pages 1365 - 1369 | - |
| DESCRIPTION | - DONG H et al., Nat Med, (20020000), vol. 8, pages 793 - 800 | - |
| DESCRIPTION | - FREEMAN et al., J Exp Med, (20000000), vol. 192, pages 1027 - 34 | - |
| DESCRIPTION | - GANDHI M K et al., Blood, (20060000), vol. 108, pages 2280 - 2289 | - |
| DESCRIPTION | - GODING S R et al., J. Immunol., (20130000), vol. 190, no. 9, pages 4899 - 4909 | - |
| DESCRIPTION | - GODING SR et al., J Immunol., (20130000), vol. 190, pages 4899 - 4909 | - |
| DESCRIPTION | - GROSSO J F et al., J. Clin. Invest., (20070000), vol. 117, pages 3383 - 3392 | - |
| DESCRIPTION | - GROSSO JF et al., J Clin Invest., (20070000), vol. 117, pages 3383 - 3392 | - |
| DESCRIPTION | - HAMID O et al., NEJM, (20130000), vol. 369, pages 134 - 144 | - |
| DESCRIPTION | - HANSEN et al., Immunogenics, (19800000), vol. 10, pages 247 - 260 | - |
| DESCRIPTION | - HERBST et al., J Clin Oncol, (20130000), vol. 31, page 3000 | - |
| DESCRIPTION | - HUANG C T et al., Immunity, (20040000), vol. 21, pages 503 - 513 | - |
| DESCRIPTION | - HUANG CT et al., Immunity, (20040000), vol. 21, pages 503 - 513 | - |
| DESCRIPTION | - HUARD B et al., Proc Natl Acad Sci U S A., (19970000), vol. 94, pages 5744 - 5749 | - |
| DESCRIPTION | - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883 | - |
| DESCRIPTION | - HUTLOFF et al., Nature, (19990000), vol. 397, pages 263 - 266 | - |
| DESCRIPTION | - ISHIDA et al., EMBO J, (19920000), vol. 11, pages 3887 - 95 | - |
| DESCRIPTION | - IWAI et al., Proc. Nat'l. Acad. Sci. USA, (20020000), vol. 99, pages 12293 - 7 | - |
| DESCRIPTION | - J. MATSUZAKI et al., PNAS, (20100000), vol. 107, page 7875 | - |
| DESCRIPTION | - Journal for ImmunoTherapy of Cancer, (20160000), vol. 4, no. 1 | - |
| DESCRIPTION | - KEIR M E et al., Annu Rev Immunol, (20080000), vol. 26, pages 677 - 704 | - |
| DESCRIPTION | - KONISHI et al., Clin. Cancer Res., (20040000), vol. 10, pages 5094 - 100 | - |
| DESCRIPTION | - LATCHMAN et al., Nat Immunol, (20010000), vol. 2, pages 261 - 8 | - |
| DESCRIPTION | - LIPSON E et al., J Immunother Cancer, (20160000), vol. 4, no. 1, page 173 | - |
| DESCRIPTION | - LIPSON et al., J Immunother Cancer., (20160000), vol. 4, page 173 | - |
| DESCRIPTION | - LYFORD-PIKE S et al., Cancer Res., (20130000), vol. 73, no. 6, pages 1733 - 41 | - |
| DESCRIPTION | - MATSUZAKI J et al., Proc. Natl. Acad. Sci., USA, (20100000), vol. 107, pages 7875 - 7880 | - |
| DESCRIPTION | - MCCABE; WU, Cancer Biother. Radiopharm., (20100000), vol. 25, no. 3, pages 253 - 61 | - |
| DESCRIPTION | - NIELSEN et al., Lupus, (20040000), vol. 13, page 510 | - |
| DESCRIPTION | - NISHIMURA et al., Immunity, (19990000), vol. 11, pages 141 - 51 | - |
| DESCRIPTION | - NISHIMURA et al., Science, (20010000), vol. 291, pages 319 - 22 | - |
| DESCRIPTION | - NISHIMURA H et al., Immunity, (19990000), vol. 11, pages 141 - 151 | - |
| DESCRIPTION | - NISHIMURA H et al., Science, (20010000), vol. 291, pages 319 - 322 | - |
| DESCRIPTION | - OKAZAKI et al., Curr. Opin. Immunol., (20020000), vol. 14, pages 391779 - 82 | - |
| DESCRIPTION | - OKAZAKI et al., PNAS, (20010000), vol. 98, pages 13866 - 71 | - |
| DESCRIPTION | - OKAZAKI T et al., J. Exp Med., (20110000), vol. 208, pages 395 - 407 | - |
| DESCRIPTION | - OLAFSEN et al., Protein Eng. Des. Sel., (20100000), vol. 23, no. 4, pages 243 - 9 | - |
| DESCRIPTION | - ORCHARD; CALONJE, Am J Dermatopathol, (19980000), vol. 20, no. 4, pages 357 - 61 | - |
| DESCRIPTION | - PARDOLL D M., Nat Rev Cancer, (20120000), vol. 12, pages 252 - 264 | - |
| DESCRIPTION | - PROKUNINA; ALARCON-RIQUELME, Hum Mol Genet, (20040000), vol. 13, page R143 | - |
| DESCRIPTION | - SALAMA et al., J Exp Med, (20030000), vol. 198, pages 71 - 78 | - |
| DESCRIPTION | - SHEN; WU, Appl Immunohistochem Mol Morphol, (20150000), vol. 23, no. 4, pages 303 - 307 | - |
| DESCRIPTION | - SIERRO S et al., Expert Opin Ther Targets., (20110000), vol. 15, pages 91 - 101 | - |
| DESCRIPTION | - SI-YANG LIU et al., J. Hematol. Oncol., (20170000), vol. 10, page 136 | - |
| DESCRIPTION | - TERME M et al., Cancer Res, (20110000), vol. 71, pages 5393 - 5399 | - |
| DESCRIPTION | - THOMAS, M. L., J Exp Med, (19950000), vol. 181, pages 1953 - 6 | - |
| DESCRIPTION | - TOPALIAN S L et al., NEJM, (20120000), vol. 366, no. 26, pages 2443 - 2454 | - |
| DESCRIPTION | - TRIEBEL F et al., J. Exp. Med., (19900000), vol. 171, pages 1393 - 1405 | - |
| DESCRIPTION | - VIVIER, E; DAERON, M, Immunol Today, (19970000), vol. 18, pages 286 - 91 | - |
| DESCRIPTION | - WANG et al., Cancer Immunol Res, (20140000), vol. 2, no. 9, pages 846 - 56 | - |
| DESCRIPTION | - WANG et al., Cancer Immunol Res., (20140000), vol. 2, no. 9, pages 846 - 56 | - |
| DESCRIPTION | - WARD et al., Nature, (19890000), vol. 341, pages 544 - 46 | - |
| DESCRIPTION | - WHERRY, Nat Immunol., (20110000), vol. 12, no. 6, pages 492 - 9 | - |
| DESCRIPTION | - WOO S R et al., Cancer Res., (20120000), vol. 72, pages 917 - 927 | - |
| DESCRIPTION | - WOO SR et al., Cancer Res., (20120000), vol. 72, pages 917 - 927 | - |
| DESCRIPTION | - WORKMAN C J et al., J. Immunol., (20050000), vol. 174, pages 688 - 695 | - |
| DESCRIPTION | - WORKMAN C J et al., J. Immunol., (20090000), vol. 182, no. 4, pages 1885 - 91 | - |
| DESCRIPTION | - ZHANG et al., Cell Discov., (20170300), vol. 7, page 3 | - |
| EXAMINATION | - Anonymous, "2017 ASCO Annual Meeting Preview and Education Program Highlights | ASCO Connection", (20170302), pages 1 - 10, URL: https://connection.asco.org/magazine/features/2017-asco-annual-meeting-preview-and-education-program-highlights, (20210831), XP055836450 | - |
| EXAMINATION | - anonymous, "Email exchange", (20210831), URL: www.epo.org, XP055836861 | - |
| EXAMINATION | - ASCIERTO PAOLO ANTONIO ET AL, "Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy.", JOURNAL OF CLINICAL ONCOLOGY, US, (20170520), vol. 35, no. 15_suppl, doi:10.1200/JCO.2017.35.15_suppl.9520, ISSN 0732-183X, pages 9520 - 9520, XP055774192 | |
| INTERNATIONAL-SEARCH-REPORT | - N. J. LLOSA ET AL, "The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints", CANCER DISCOVERY, US, (20141030), vol. 5, no. 1, doi:10.1158/2159-8290.CD-14-0863, ISSN 2159-8274, pages 43 - 51, XP055390935 [X] 1-28 * abstract * [I] 142-237 | |
| INTERNATIONAL-SEARCH-REPORT | - Y. XIAO ET AL, "The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy", CANCER DISCOVERY, US, (20150112), vol. 5, no. 1, doi:10.1158/2159-8290.CD-14-1397, ISSN 2159-8274, pages 16 - 18, XP055271983 [X] 1-28 * abstract * [I] 142-237 | |
| INTERNATIONAL-SEARCH-REPORT | - R. F. SWEIS ET AL, "Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer", CANCER IMMUNOLOGY RESEARCH, US, (20160517), vol. 4, no. 7, doi:10.1158/2326-6066.CIR-15-0274, ISSN 2326-6066, pages 563 - 568, XP055499277 [X] 1-28 * abstract * [I] 142-237 | |
| OPPOSITION | - Anonymous, "Opdualag 240 mg/80 mg concentrate for solution for infusion", SUMMARY OF PRODUCT CHARACTERISTICS, European Medicines Agency, pages 1 - 42, SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf, XP093307695 | - |
| OPPOSITION | - A Study To Evaluate The Safety, Tolerability, And Efficacy Of Relatlimab In Relapsed Or Refractory B-Cell Malignancies, "NCT02061761 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies ", ClinicalTrials.gov, NLM, pages 1 - 19, ClinicalTrials.gov, URL: https://www.clinicaltrials.gov/study/NCT02061761?tab=history&a=48#version-content-panel, XP093307642 | - |
| OPPOSITION | - Bristol-Myers Squibb, "NCT01968109 | An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors", ClinicalTrials.gov, NLM, pages 1 - 26, ClinicalTrials.gov, URL: https://www.clinicaltrials.gov/study/NCT01968109?tab=history&a=51#version-content-panel, XP093307773 | - |
| OPPOSITION | - Bristol-Myers Squibb, "NCT02750514 | An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)", ClinicalTrials.gov, NLM, pages 1 - 27, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02750514?tab=history&a=30#version-content-panel, XP093307699 | - |
| OPPOSITION | - D36 - 2017 ASCO Annual Meeting Preview and Education Program Highlights (as proof of the publication date of Ascierto et al. on May 17, 2017, at 5:00 PM) | - |
| OPPOSITION | - D37 - Office Action dated September 08, 2021 during prosecution of the Opposed Patent | - |
| OPPOSITION | - D49 - EP 18735009.5, Proprietor’s Response to Examination Report; dated 18 Jan 2022 | - |
| OPPOSITION | - D53 - Experimental report and declaration of Dr. Nathalie Fiaschi dated 9 July 2025 | - |
| OPPOSITION | - D54 - Ex. 1 to D55: Short CV of Dr. Nathalie Fiaschi | - |
| OPPOSITION | - D57 - Expert Opinion of Prof. Fred R. Hirsch with enclosures D58 to D60 (“Ex. 1” to “Ex. 3”) | - |
| OPPOSITION | - D58 - CV of Prof. Hirsch | - |
| OPPOSITION | - Ema, European Medicines Agency, "Assessment report: Opdualag; Procedure No. EMEA/H/C/005481/0000", URL: https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag, XP093294784 | - |
| OPPOSITION | - Evan Lipson, Ajay Gopal, Sattva S Neelapu, Philippe Armand, Stephen Spurgeon, John P Leonard, F Stephen Hodi, Rachel E Sanborn, Ignacio Melero, Thomas F Gajewski, Matthew Maurer, Serena Perna, Andres A Gutierrez, Raphael Clynes, Priyam Mitra, Satyendra Suryawanshi, Douglas Gladstone, Margaret K Callahan, "P232 Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies", Journal for ImmunoTherapy of Cancer, BioMed Central, London, GB, GB , (20161116), vol. 4, no. S1, ISSN 2051-1426, pages 129 - 130, XP009556549 | - |
| OPPOSITION | - Fda-Nih Biomarker Working Group Best, "Understanding Prognostic versus Predictive Biomarkers", BEST (Biomarkers, EndpointS, and other Tools) Resource, National Institutes of Health (US), pages 1 - 4, BEST (Biomarkers, EndpointS, and other Tools) Resource , URL: https://www.ncbi.nlm.nih.gov/books/NBK402284/pdf/Bookshelf_NBK402284.pdf, (20211111), XP055860329 | - |
| OPPOSITION | - Novartis Pharmaceuticals, "NCT02460224 | Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.", ClinicalTrials.gov, NLM, pages 1 - 19, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT02460224?tab=history&a=11#version-content-panel, XP093307755 | - |
| OPPOSITION | - Tsao Ming Sound, Kerr Keith M, Yatabe Yasushi, Hirsch Fred R, "IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer", IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer, International Association for the Study of Lung Cancer, Aurora, CO, USA, Aurora, CO, USA, ISBN 978-0-9832958-7-7, pages 1 - 132, IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer, URL: https://raw.githubusercontent.com/awiloQMH/CancerReportingTemplate/master/cap/iaslc_pd-l1_atlas_mar2018_lo-res.pdf, XP093307829 | - |
| OPPOSITION | - David F. Mcdermott, Michael B. Atkins, "PD-1 as a potential target in cancer therapy", Cancer Medicine, Wiley, (20130721), doi:10.1002/cam4.106, ISSN 20457634, pages n/a - n/a, XP055157252 | |
| OPPOSITION | - Seng‐Ryong Woo; Nianyu Li; Tullia C. Bruno; Karen Forbes; Scott Brown; Creg Workman; Charles G. Drake; Dario A. A. Vignali, "Differential subcellular localization of the regulatory T‐cell protein LAG‐3 and the coreceptor CD4", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (20100409), vol. 40, no. 6, doi:10.1002/eji.200939874, ISSN 0014-2980, pages 1768 - 1777, XP071225481 | |
| OPPOSITION | - Jeffrey Prichard, David Hicks, Elizabeth Hammond , "Chapter 9: Predictive Markers of Breast Cancer: ER, PR, and HER2", Jeffrey Prichard, David Hicks, Elizabeth Hammond , Lin et al., Handbook of practical immunohistochemistry: frequently asked questions, Springer Nature, (20110101), pages 103 - 117, doi:10.1007/978-1-4419-8062-5_9, ISBN 978-1-4419-8061-8, XP009562687 | |
| OPPOSITION | - Ivanova Mariia, Porta Francesca Maria, D’ercole Marianna, Pescia Carlo, Sajjadi Elham, Cursano Giulia, De Camilli Elisa, Pala Oriana, Mazzarol Giovanni, Venetis Konstantinos, Guerini-Rocco Elena, Curigliano Giuseppe, Viale Giuseppe, Fusco Nicola, "Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer", Virchows Archiv, Berlin/Heidelberg, (20240101), vol. 484, no. 1, doi:10.1007/s00428-023-03656-w, ISSN 0945-6317, pages 3 - 14, XP093299109 | |
| OPPOSITION | - Ulase Dita, Behrens Hans-Michael, Krüger Sandra, Heckl Steffen M., Ebert Ulrike, Becker Thomas, Röcken Christoph, "LAG3 in gastric cancer: it’s complicated", Journal of Cancer Research and Clinical Oncology, SPRINGER INTERNATIONAL, BERLIN., DE, DE , (20230901), vol. 149, no. 12, doi:10.1007/s00432-023-04954-1, ISSN 0171-5216, pages 10797 - 10811, XP093307780 | |
| OPPOSITION | - Chen Jinxiang, Chen Zihua, "The effect of immune microenvironment on the progression and prognosis of colorectal cancer", MEDICAL ONCOLOGY, SCIENCE AND TECHNOLOGY LETTERS, NORTHWOOD, GB, GB , (20140801), vol. 31, no. 8, doi:10.1007/s12032-014-0082-9, ISSN 1357-0560, pages 82 - 8, XP093307647 | |
| OPPOSITION | - Robert, Et Al., "Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies", Eur. J. Cancer., (20130729), vol. 49, no. 14, doi:10.1016/j.ejca.2013.07.001, pages 2968 - 2971, XP055632318 | |
| OPPOSITION | - Huang Ching-Tai; Workman Creg J; Flies Dallas; Pan Xiaoyu; Marson Aimee L; Zhou Gang; Hipkiss Edward L; Ravi Sowmya; Kowalski Jeanne; Levitsky Hyam I; Powell Jonathan D; Pardoll Drew M; Drake Charles G; Vignali Dario A A, "Role of LAG-3 in regulatory T cells", Immunity, Cell Press, AMSTERDAM, NL, AMSTERDAM, NL , (20041001), vol. 21, no. 4, doi:10.1016/j.immuni.2004.08.010, ISSN 1074-7613, pages 503 - 513, XP009138514 | |
| OPPOSITION | - Fred R. Hirsch, Mcelhinny Abigail, Stanforth Dave, Ranger-Moore James, Jansson Malinka, Kulangara Karina, Richardson William, Towne Penny, Hanks Debra, Vennapusa Bharathi, Mistry Amita, Kalamegham Rasika, Averbuch Steve, Novotny James, Rubin Eric, Emancipator Kenneth, Mccaffery Ian, Williams J. Andrew, Walker Jill, Longshore John, Tsao Ming Sound, Kerr Keith M., "PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project", Journal of thoracic oncology, Elsevier Inc, (20170201), vol. 12, no. 2, doi:10.1016/j.jtho.2016.11.2228, ISSN 1556-0864, pages 208 - 222, XP055653634 | |
| OPPOSITION | - He Yayi, Hui Yu, Leslie Rozeboom, Christopher J. Rivard, Kim Ellison, Rafal Dziadziuszko, Kenichi Suda, Shengxiang Ren, Chunyan Wu, Likun Hou, Caicun Zhou, Fred R. Hirsch, "Supplementary Data: LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes", Journal of thoracic oncology, Elsevier Inc, (20170501), vol. 12, no. 5, doi:10.1016/j.jtho.2017.01.019, ISSN 1556-0864, pages 1 - 4, XP093307689 | |
| OPPOSITION | - Yayi He, Hui Yu, Leslie Rozeboom, Christopher J. Rivard, Kim Ellison, Rafal Dziadziuszko, Kenichi Suda, Shengxiang Ren, Chunyan Wu, Likun Hou, Caicun Zhou, Fred R. Hirsch, "LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes", Journal of thoracic oncology, Elsevier Inc, (20170501), vol. 12, no. 5, doi:10.1016/j.jtho.2017.01.019, ISSN 1556-0864, pages 814 - 823, XP093156015 | |
| OPPOSITION | - Robert Marie E., Rüschoff Josef, Jasani Bharat, Graham Rondell P., Badve Sunil S., Rodriguez-Justo Manuel, Kodach Liudmila L., Srivastava Amitabh, Wang Hanlin L., Tang Laura H., Troncone Giancarlo, Rojo Federico, Van Treeck Benjamin J., Pratt James, Shnitsar Iryna, Kumar George, Karasarides Maria, Anders Robert A., "High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma", Modern Pathology, New York, (20230501), vol. 36, no. 5, doi:10.1016/j.modpat.2023.100154, ISSN 0893-3952, pages 1 - 11, XP093299104 | |
| OPPOSITION | - Demeure, C.E. Wolfers, J. Martin-Garcia, N. Gaulard, P. Triebel, F., "T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts", European Journal of Cancer, Elsevier, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, (20010901), vol. 37, no. 13, doi:10.1016/S0959-8049(01)00184-8, ISSN 0959-8049, pages 1709 - 1718, XP004301143 | |
| OPPOSITION | - Paul C. Tumeh, Harview Christina L., Yearley Jennifer H., Shintaku I. Peter, Taylor Emma J. M., Robert Lidia, Chmielowski Bartosz, Spasic Marko, Henry Gina, Ciobanu Voicu, West Alisha N., Carmona Manuel, Kivork Christine, Seja Elizabeth, Cherry Grace, Gutierrez Antonio J., Grogan Tristan R., Mateus Christine, Tomasic Gorana, Glaspy John A., Emerson Ryan O., Robins Harlan, Pierce Robert H., Elashoff David A., Robert Caroline, Ribas Antoni, "PD-1 blockade induces responses by inhibiting adaptive immune resistance", Nature, Springer Nature Limited, London, London, (20141127), vol. 515, no. 7528, doi:10.1038/nature13954, ISSN 0028-0836, pages 568 - 571, XP055247294 | |
| OPPOSITION | - TOPALIAN SUZANNE L ET AL, "Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.", Cancer stem cells in solid tumours: accumulating evidence and unresolved questions., (20160415), vol. 16, no. 5, doi:10.1038/nrc.2016.36, ISSN 1474-1768, pages 275 - 287, XP002771342 | |
| OPPOSITION | - Linh T. Nguyen, Pamela S. Ohashi, "Clinical blockade of PD1 and LAG3 — potential mechanisms of action", Nature Reviews Immunology, Nature Publishing Group UK, London, London, (00150101), vol. 15, no. 1, doi:10.1038/nri3790, ISSN 1474-1733, pages 45 - 56, XP055216541 | |
| OPPOSITION | - Luke Jason J., Patel Manish R., Blumenschein George R., Hamilton Erika, Chmielowski Bartosz, Ulahannan Susanna V., Connolly Roisin M., Santa-Maria Cesar A., Wang Jie, Bahadur Shakeela W., Weickhardt Andrew, Asch Adam S., Mallesara Girish, Clingan Philip, Dlugosz-Danecka Monika, Tomaszewska-Kiecana Monika, Pylypenko Halyna, Hamad Nada, Kindler Hedy L., Sumrow Bradley J., Kaminker Patrick, Chen Francine Z., Zhang Xiaoyu, Shah Kalpana, Smith Douglas H., De Costa Anushka, Li Jonathan, Li Hua, Sun Jichao, Moore Paul A., "Supplementary Information: The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial", Nature Medicine(Author manuscript ), Nature Publishing Group US, New York, New York, (20231101), vol. 29, no. 11, doi:10.1038/s41591-023-02593-0, ISSN 1078-8956, pages 1 - 22, XP093307796 | |
| OPPOSITION | - Luke Jason J., Patel Manish R., Blumenschein George R., Hamilton Erika, Chmielowski Bartosz, Ulahannan Susanna V., Connolly Roisin M., Santa-Maria Cesar A., Wang Jie, Bahadur Shakeela W., Weickhardt Andrew, Asch Adam S., Mallesara Girish, Clingan Philip, Dlugosz-Danecka Monika, Tomaszewska-Kiecana Monika, Pylypenko Halyna, Hamad Nada, Kindler Hedy L., Sumrow Bradley J., Kaminker Patrick, Chen Francine Z., Zhang Xiaoyu, Shah Kalpana, Smith Douglas H., De Costa Anushka, Li Jonathan, Li Hua, Sun Jichao, Moore Paul A., "The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial", Nature Medicine(Author manuscript ), Nature Publishing Group US, New York, New York, (20231101), vol. 29, no. 11, doi:10.1038/s41591-023-02593-0, ISSN 1078-8956, pages 2814 - 2824, XP093114053 | |
| OPPOSITION | - Tawbi Hussein A; Schadendorf Dirk; Lipson Evan J; Ascierto Paolo A; Matamala Luis; Castillo Gutiérrez Erika; Rutkowski Piotr; Gogas Helen J; Lao Christopher D; De Menezes Juliana Janoski; Dalle Stéphane; Arance Ana; Grob Jean-Jacques; Srivastava Shivani; Abaskharoun Mena; Hamilton Melissa; Keidel Sarah; Simonsen Katy L; Sobiesk Anne Marie; Li Bin; Hodi F Stephen; Long Georgina V; , "Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.", New England Journal of Medicine, The - NEJM, Massachusetts Medical Society, US, US , (20220106), vol. 386, no. 1, doi:10.1056/NEJMoa2109970, ISSN 1533-4406, pages 24 - 34, XP009532953 | |
| OPPOSITION | - J. Matsuzaki, S. Gnjatic, P. Mhawech-Fauceglia, A. Beck, A. Miller, T. Tsuji, C. Eppolito, F. Qian, S. Lele, P. Shrikant, L. J. Old, K. Odunsi, "Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20100427), vol. 107, no. 17, doi:10.1073/pnas.1003345107, ISSN 00278424, pages 7875 - 7880, XP055147797 | |
| OPPOSITION | - Deng Wei-Wei, Mao Liang, Yu Guang-Tao, Bu Lin-Lin, Ma Si-Rui, Liu Bing, Gutkind J. Silvio, Kulkarni Ashok B., Zhang Wen-Feng, Sun Zhi-Jun, "LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma", OncoImmunology, (20161101), vol. 5, no. 11, doi:10.1080/2162402X.2016.1239005, ISSN 2162-402X, page e1239005, XP093193159 | |
| OPPOSITION | - Huang Ruea-Yea, Francois Ariel, Mcgray Aj Robert, Miliotto Anthony, Odunsi Kunle, "Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer", Oncoimmunolgy, Landes Bioscience, US, US , (20170102), vol. 6, no. 1, doi:10.1080/2162402X.2016.1249561, ISSN 2162-4011, pages e1249561 - 13, XP055980549 | |
| OPPOSITION | - TRIEBEL F., ET AL., "LAG-3 A NOVEL LYMPHOCYTE ACTIVATION GENE CLOSELY RELATED TO CD4.", Journal of Experimental Medicine, Rockefeller University Press, US, US , (19900501), vol. 171., no. 05., doi:10.1084/jem.171.5.1393, ISSN 0022-1007, pages 1393 - 1405., XP000672284 | |
| OPPOSITION | - Ascierto P. A., P. Bono, S. Bhatia, Melero, M.S. Nyakas, I-M. Svane, J. Larkin, C. Gomez-Roca, D. Schadendorf, R. Dummer, A. Marabelle, C. Hoeller, M. Maurer, C.T. Harbison, P. Mitra, S. Suryawanshi, K. Thudium, E. Muñoz Couselo, "LBA18 - Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations", Annals of Oncology, Elsevier Ltd, (20170901), vol. 28, no. Suppl. 5, doi:10.1093/annonc/mdx440, ISSN 0923-7534, pages 611 - 612, XP093307790 | |
| OPPOSITION | - Yayi He, Et Al., "Lymphocyte-activation gene-3, an important immune checkpoint in cancer", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, JP , (20160901), vol. 107, no. 9, doi:10.1111/cas.12986, ISSN 1347-9032, pages 1193 - 1197, XP055540244 | |
| OPPOSITION | - Lawrence P. Andrews, Ariel E. Marciscano, Charles G. Drake, Dario A. A. Vignali, "LAG3 (CD223) as a cancer immunotherapy target", Immunological Reviews, US , (20170301), vol. 276, no. 1, doi:10.1111/imr.12519, ISSN 0105-2896, pages 80 - 96, XP055717792 | |
| OPPOSITION | - S.-R. Woo, M. E. Turnis, M. V. Goldberg, J. Bankoti, M. Selby, C. J. Nirschl, M. L. Bettini, D. M. Gravano, P. Vogel, C. L. Liu, S. Tangsombatvisit, J. F. Grosso, G. Netto, M. P. Smeltzer, A. Chaux, P. J. Utz, C. J. Workman, D. M. Pardoll, A. J. Korman, C. G. Drake, D. A. A. Vignali, "Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape", Cancer research, American Association for Cancer Research, San Diego, CA . Philadelphia (PA, San Diego, CA . Philadelphia (PA, (20120215), vol. 72, no. 4, doi:10.1158/0008-5472.CAN-11-1620, ISSN 0008-5472, pages 917 - 927, XP055431013 | |
| OPPOSITION | - Tassi Elena, Grazia Giulia, Vegetti Claudia, Bersani Ilaria, Bertolini Giulia, Molla Alessandra, Baldassari Paola, Andriani Francesca, Roz Luca, Sozzi Gabriella, Pastorino Ugo, Mortarini Roberta, Anichini Andrea, "Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer", Cancer research, American Association for Cancer Research, San Diego, CA . Philadelphia (PA, San Diego, CA . Philadelphia (PA, (20170215), vol. 77, no. 4, doi:10.1158/0008-5472.CAN-16-1387, ISSN 0008-5472, pages 851 - 861, XP055847089 | |
| OPPOSITION | - S. P. Patel, R. Kurzrock, "PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20150401), vol. 14, no. 4, doi:10.1158/1535-7163.MCT-14-0983, ISSN 1535-7163, pages 847 - 856, XP055431490 | |
| OPPOSITION | - N. J. Llosa, M. Cruise, A. Tam, E. C. Wicks, E. M. Hechenbleikner, J. M. Taube, R. L. Blosser, H. Fan, H. Wang, B. S. Luber, M. Zhang, N. Papadopoulos, K. W. Kinzler, B. Vogelstein, C. L. Sears, R. A. Anders, D. M. Pardoll, F. Housseau, "The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20150101), vol. 5, no. 1, doi:10.1158/2159-8290.CD-14-0863, ISSN 2159-8274, pages 43 - 51, XP055390935 | |
| OPPOSITION | - Y. Xiao, Freeman G. J., "The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20150101), vol. 5, no. 1, doi:10.1158/2159-8290.CD-14-1397, ISSN 2159-8274, pages 16 - 18, XP055271983 | |
| OPPOSITION | - LaurenceP. Diggs;EddyC. Hsueh, "Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response", Biomarker Research, BioMed Central Ltd, London, UK, London, UK , (20170315), vol. 5, no. 1, doi:10.1186/s40364-017-0093-8, pages 1 - 6, XP021243204 | |
| OPPOSITION | - Burova Elena, Omaira Allbritton, Peter Hong, Jie Dai, Jerry Pei, Matt Liu, Joel Kantrowitz, Venus Lai, William Poueymirou, Douglas Macdonald, Ella Ioffe, Markus Mohrs, William Olson, Gavin Thurston , "P195 A novel anti-human LAG-3 antibody in combination with antihuman PD-1 (REGN2810) shows enhanced anti-tumor activity in PD-1 x LAG-3 dual-humanized mice and favorable pharmacokinetic and safety profiles in cynomolgus monkeys", Journal for ImmunoTherapy of Cancer, GB , (20161101), vol. 4, no. S1, doi:10.1186/s40425-016-0173-6, ISSN 2051-1426, pages 111 - 111, XP093307762 | |
| OPPOSITION | - Casey Ager;Matthew Reilley;Courtney Nicholas;Todd Bartkowiak;Ashvin Jaiswal;Michael Curran;TinaC. Albershardt;Anshika Bajaj;JacobF. Archer;RebeccaS. Reeves;LisaY. Ngo;Peter Berglund;Jan ter Meulen;Caroline Denis;Hormas Ghadially;Thomas Arnoux;Fabien Chanuc;Nicolas Fuseri;RobertW. Wilkinson;Nicolai Wagtmann;Yannis Morel;Pascale Andre;MichaelB. Atkins;MatteoS. Carlino;Antoni Ribas;JohnA. Thompson;ToniK. Choueiri;F.Stephen Hodi;Wen-Jen Hwu;DavidF. McDermott;Victoria Atkinson;JonathanS. Cebon;Bernie Fitzharris;MichaelB. Jameson;Catriona McNeil;AndrewG. Hill;Eric Mangin;Malidi Ahamadi;Marianne van Vugt;Mariëlle van Zutphen;Nageatte Ibrahim;GeorginaV. Long;Robyn Gartrell;Zoe Blake;Ines Simoes;Yichun Fu;Takuro Saito;Yingzhi Qian;Yan Lu;YvonneM. Saenger;Sadna Budhu;Olivier De Henau;Roberta Zappasodi;Kyle Schlunegger;Bruce Freimark;Jeff Hutchins;ChristopherA. Barker;JeddD. Wolchok;Taha Merghoub;Elena Burova;Omaira Allbritton;Peter Hong;Jie Dai;Jerry Pei;Matt Liu;Joel Kantrowitz;Venus Lai;W, "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two", illiaJournal for ImmunoTherapy of C, BioMed Central Ltd, London, UK, London, UK , (20161116), vol. 4, no. 1, doi:10.1186/s40425-016-0173-6, pages 107 - 221, XP021241441 | |
| OPPOSITION | - Hammond M. Elizabeth, Hayes Daniel F., Dowsett Mitch, Allred D. Craig, Hagerty Karen L., Badve Sunil, Fitzgibbons Patrick L., Francis Glenn, Goldstein Neil S., Hayes Malcolm, Hicks David G., Lester Susan, Love Richard, Mangu Pamela B., Mcshane Lisa, Miller Keith, Osborne C. Kent, Paik Soonmyung, Perlmutter Jane, Rhodes Anthony, Sasano Hironobu, Schwartz Jared N., Sweep Fred C.G., Taube Sheila, Torlakovic Emina Emilia, Valenstein Paul, Viale Giuseppe, Visscher Daniel, Wheeler Thomas, Williams R. Bruce, Wittliff James L., Wolff Antonio C., "American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer", Journal of Clinical Oncology, American Society of Clinical Oncology, (20100601), vol. 28, no. 16, doi:10.1200/JCO.2009.25.6529, ISSN 0732-183X, pages 2784 - 2795, XP093307831 | |
| OPPOSITION | - Ascierto Paolo Antonio, Melero Ignacio, Bhatia Shailender, Bono Petri, Sanborn Rachel E., Lipson Evan J., Callahan Margaret K., Gajewski Thomas, Gomez-Roca Carlos A., Hodi F. Stephen, Curigliano Giuseppe, Nyakas Marta, Preusser Matthias, Koguchi Yoshinobu, Maurer Matthew, Clynes Raphael, Mitra Priyam, Suryawanshi Satyendra, Muñoz-Couselo Eva, "Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy.", Journal of Clinical Oncology, Grune & Stratton, (20170520), vol. 35, no. 15_suppl, doi:10.1200/JCO.2017.35.15_suppl.9520, ISSN 0732-183X, pages 9520 - 9520, XP055774192 | |
| OPPOSITION | - Hamid Omid, Lewis Karl D., Weise Amy M., Mckean Meredith, Papadopoulos Kyriakos P., Crown John, Thomas Sajeve Samuel, Girda Eugenia, Kaczmar John M., Kim Kevin B., Lakhani Nehal, Yushak Melinda Lynne, Mani Jayakumar, Fang Fang, Brennan Laura, Jankovic Vladimir, Paccaly Anne Josee, Masinde Sheila, Lowy Israel, Gullo Giuseppe, "Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.", Journal of Clinical Oncology, Grune & Stratton, (20230601), vol. 41, no. 16_suppl, doi:10.1200/JCO.2023.41.16_suppl.9501, ISSN 0732-183X, pages 9501 - 9501, XP093193165 | |
| OPPOSITION | - Ascierto Paolo Antonio, Dummer Reinhard, Gaudy-Marqueste Caroline, Bowyer Samantha, Lipson Evan J., Ghisoni Eleonora, Middleton Mark R., Ratto Barbara, Jackson William Joseph, Cheong Alicia, Mukherjee Sourav, Wu Jenny, Long Georgina V., "Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab in advanced melanoma: results from RELATIVITY-048 (Abstract number 9504)", Journal of Clinical Oncology, American Society of Clinical Oncology, (20240601), vol. 42, no. 16_suppl, doi:10.1200/JCO.2024.42.16_suppl.9504, ISSN 0732-183X, pages 1 - 18, XP093307813 | |
| OPPOSITION | - Ascierto Paolo Antonio, Lipson Evan J, Dummer Reinhard, Larkin James, Long Georgina V, Sanborn Rachel E, Chiarion-Sileni Vanna, Brigitte ;, Dalle Stéphane, Schadendorf Dirk, Callahan Margaret K, Nyakas Marta, Atkinson Victoria, Carlos ;, Gomez-Roca Alberto, Yamazaki Naoya, Tawbi Hussein A, Sarkis Naomey, Warad Deepti, Dolfi Sonia, Mitra Priyam, Suryawanshi Satyendra, Grob Jean-Jacques, "Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial", (20230520), vol. 41, no. 15, doi:10.1200/JCO.22.02072, pages 2724 - 2735, XP093193163 | |
| OPPOSITION | - Hegewisch-Becker Susanna, Mendez Guillermo, Chao Joseph, Nemecek Radim, Feeney Kynan, Van Cutsem Eric, Al-Batran Salah-Eddin, Mansoor Wasat, Maisey Nicholas, Pazo Cid Roberto, Burge Matthew, Perez-Callejo David, Hipkin R. William, Mukherjee Sourav, Lei Ming, Tang Hao, Suryawanshi Satyendra, Kelly Ronan J., Tebbutt Niall C., "First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study", Journal of Clinical Oncology, American Society of Clinical Oncology, (20240610), vol. 42, no. 17, doi:10.1200/JCO.23.01636, ISSN 0732-183X, pages 2080 - 2093, XP093246164 | |
| OPPOSITION | - Jan Budczies, Frederick Klauschen, Bruno Sinn, Balázs Győrffy, Wolfgang Schmitt, Silvia Darb Esfahani, Carsten Denkert, Paul Van Diest, "Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization", PLoS ONE, Public Library of Science, (20121214), vol. 7, no. 12, doi:10.1371/journal.pone.0051862, page e51862, XP055553569 | |
| OPPOSITION | - Kotaskova Jana, Tichy Boris, Trbusek Martin, Francova Hana Skuhrova, Kabathova Jitka, Malcikova Jitka, Doubek Michael, Brychtova Yvona, Mayer Jiri, Pospisilova Sarka, "High Expression of Lymphocyte-Activation Gene 3 (LAG3) in Chronic Lymphocytic Leukemia Cells Is Associated with Unmutated Immunoglobulin Variable Heavy Chain Region (IGHV) Gene and Reduced Treatment-Free Survival", The Journal of Molecular Diagnostics, American Society for Investigative Pathology and the Association for Molecular Pathology, (20100501), vol. 12, no. 3, doi:10.2353/jmoldx.2010.090100, ISSN 1525-1578, pages 328 - 334, XP093307684 | |
| OPPOSITION | - Saleh Ramy R., Peinado Paloma, Fuentes-Antrás Jesús, Pérez-Segura Pedro, Pandiella Atanasio, Amir Eitan, Ocaña Alberto, "Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis", Frontiers in Oncology, Frontiers Media S.A., (20191015), vol. 9, doi:10.3389/fonc.2019.01040, ISSN 2234-943X, pages 1040 - 9, XP093307784 | |
| OPPOSITION | - Workman Creg J., Wang Yao, El Kasmi Karim C., Pardoll Drew M., Murray Peter J., Drake Charles G., Vignali Dario A. A., "LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis", The Journal of Immunology, Williams & Wilkins Co., US, US , (20090215), vol. 182, no. 4, doi:10.4049/jimmunol.0800185, ISSN 0022-1767, pages 1885 - 1891, XP093193156 | |
| OPPOSITION | - Camisaschi Chiara, Casati Chiara, Rini Francesca, Perego Michela, De Filippo Annamaria, Triebel Frédéric, Parmiani Giorgio, Belli Filiberto, Rivoltini Licia, Castelli Chiara, "LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites", The Journal of Immunology, American Association of Immunologists, (20100601), vol. 184, no. 11, doi:10.4049/jimmunol.0903879, ISSN 0022-1767, pages 6545 - 6551, XP093307637 | |
| OPPOSITION | - Hemon Patrice, Jean-Louis Francette, Ramgolam Kiran, Brignone Chrystelle, Viguier Manuelle, Bachelez Hervé, Triebel Frédéric, Charron Dominique, Aoudjit Fawzi, Al-Daccak Reem, Michel Laurence, "MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis", The Journal of Immunology, Williams & Wilkins Co., US, US , (20110501), vol. 186, no. 9, doi:10.4049/jimmunol.1002050, ISSN 0022-1767, pages 5173 - 5183, XP093193157 | |
| OPPOSITION | - S. R. Goding, K. A. Wilson, Y. Xie, K. M. Harris, A. Baxi, A. Akpinarli, A. Fulton, K. Tamada, S. E. Strome, P. A. Antony, "Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma", The Journal of Immunology, American Association of Immunologists, (20130501), vol. 190, no. 9, doi:10.4049/jimmunol.1300271, ISSN 00221767, pages 4899 - 4909, XP055145038 | |
| OPPOSITION | - Workman Creg J., Vignali Dario A. A., "Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)", The Journal of Immunology, Williams & Wilkins Co., US, US , (20050115), vol. 174, no. 2, doi:10.4049/jimmunol.174.2.688, ISSN 0022-1767, pages 688 - 695, XP055795103 | |
| OPPOSITION | - Dolfi Sonia, Tang Tracy, Ao Georgina Long, Ascierto Paolo, Hodi F Stephen, Lipson Evan, Schadendorf Dirk, Wojcik John, Postelnek Jennifer, Wang Yu, Sobiesk Anne Marie, Mishra Kaushal, Keidel Sarah, Miller-Moslin Karen, Tawbi Hussein, Garnett-Benson Charlie, "606 Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology", Journal for ImmunoTherapy of Cancer, (20221101), vol. 10, no. Suppl. 2, doi:as10.1136/jitc-2022-SITC2022.0606, pages A636 - A637, XP093307805 | |
